Q2 2019 Earnings Estimate for Bausch Health Companies Inc (BHC) Issued By Piper Jaffray Companies

Bausch Health Companies Inc (NYSE:BHC) – Investment analysts at Piper Jaffray Companies increased their Q2 2019 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Tuesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now expects that the company will post earnings of $1.04 per share for the quarter, up from their previous estimate of $0.85. Piper Jaffray Companies currently has a “Neutral” rating and a $19.00 target price on the stock. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ FY2019 earnings at $4.07 EPS.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.31. The business had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 29.71%. Bausch Health Companies’s quarterly revenue was down 3.7% compared to the same quarter last year.

Several other analysts also recently weighed in on the stock. TD Securities boosted their price target on shares of Bausch Health Companies from $24.00 to $28.00 and gave the stock a “hold” rating in a research note on Wednesday. Royal Bank of Canada set a $31.00 price target on shares of Bausch Health Companies and gave the stock a “hold” rating in a research note on Wednesday. ValuEngine upgraded shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a research report on Tuesday. Morgan Stanley upgraded shares of Bausch Health Companies from an “equal weight” rating to an “overweight” rating and set a $32.00 price objective on the stock in a research report on Monday. Finally, HC Wainwright set a $25.00 price objective on shares of Bausch Health Companies and gave the company a “hold” rating in a research report on Monday, October 15th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $27.55.

Bausch Health Companies stock opened at $27.12 on Thursday. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 6.99. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of 7.08, a price-to-earnings-growth ratio of 0.38 and a beta of -0.28. Bausch Health Companies has a twelve month low of $13.86 and a twelve month high of $28.45.

In other news, Director Schutter Richard U. De acquired 125,000 shares of the firm’s stock in a transaction on Thursday, September 13th. The shares were purchased at an average price of $23.96 per share, for a total transaction of $2,995,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christina Ackermann sold 19,946 shares of the business’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The disclosure for this sale can be found here. Insiders acquired 165,000 shares of company stock worth $3,890,700 in the last 90 days. Corporate insiders own 11.54% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Bank of Montreal Can purchased a new position in shares of Bausch Health Companies during the third quarter valued at about $94,432,000. Private Management Group Inc. purchased a new position in shares of Bausch Health Companies during the second quarter valued at about $28,474,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Bausch Health Companies during the third quarter valued at about $29,915,000. Tobam purchased a new position in shares of Bausch Health Companies during the second quarter valued at about $13,886,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in shares of Bausch Health Companies during the third quarter valued at about $14,181,000. Institutional investors own 42.90% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Further Reading: The Discount Rate – What You Need to Know

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply